Healthcare [ 5/13 ] | Biotechnology [ 44/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 12, 24 | -0.22 Increased by +56.86% | -0.27 Increased by +18.52% |
| Nov 2, 23 | -0.41 Increased by +6.82% | -0.47 Increased by +12.77% |
| Aug 3, 23 | -0.43 Increased by +8.51% | -0.49 Increased by +12.24% |
| May 4, 23 | -0.53 Increased by +36.9% | -0.48 Decreased by -10.42% |
| Mar 9, 23 | -0.51 Increased by +42.7% | -0.47 Decreased by -8.51% |
| Nov 2, 22 | -0.44 Increased by +43.59% | -0.58 Increased by +24.14% |
| Aug 4, 22 | -0.47 Increased by +40.51% | -0.67 Increased by +29.85% |
| May 4, 22 | -0.84 Decreased by -13.51% | -0.73 Decreased by -15.07% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 3.24 M Decreased by -21.12% | -18.04 M Increased by +3.11% | Decreased by -556.99% Decreased by -22.82% |
| Jun 30, 23 | 6.89 M Increased by +86.46% | -18.79 M Increased by +5.69% | Decreased by -272.89% Increased by +49.42% |
| Mar 31, 23 | 2.72 M Increased by +5.91% | -22.95 M Increased by +35.55% | Decreased by -843% Increased by +39.14% |
| Dec 31, 22 | 3.54 M Increased by +863.76% | -21.89 M Increased by +41.97% | Decreased by -618.77% Increased by +93.98% |
| Sep 30, 22 | 4.11 M Increased by +167.14% | -18.62 M Increased by +43.78% | Decreased by -453.51% Increased by +78.96% |
| Jun 30, 22 | 3.69 M Increased by +139.03% | -19.92 M Increased by +33.18% | Decreased by -539.51% Increased by +72.05% |
| Mar 31, 22 | 2.57 M Increased by +182.53% | -35.62 M Decreased by -28.69% | Decreased by -1.39 K% Increased by +54.45% |
| Dec 31, 21 | 367 K Increased by +103.48% | -37.71 M Decreased by -9.57% | Decreased by -10.28 K% Decreased by -3.25 K% |
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.